Skip to main content
Top
Published in: Annals of Hematology 3/2024

27-01-2024 | Thrombotic Thrombocytopenic Purpura | Research

Largest comparison between onset and relapses of acquired thrombotic thrombocytopenic purpura reveals severe neurological involvement and worse analytic parameters at debut

Authors: Blanca Vegas Villalmanzo, Rodrigo Cantera Estefanía, Sara Muñoz Madrid, Mariana Cerrato Salas, Irene Arnaiz Martín, Marta Molina Pérez, Beatriz Sagrista López, Yolanda Ruiz Ramírez, Javier Cucharero Martín, Pablo Estival Monteliú, Paloma Ropero Gradilla, Sara Ferrer Benito, María Paz Martín Hernández, Fernando Ataulfo González Fernández, Miguel Gómez Álvarez, Ana Villegas Martínez, Celina Benavente Cuesta, Jorge Martínez Nieto

Published in: Annals of Hematology | Issue 3/2024

Login to get access

Abstract

It has been proposed that the onset of Acquired Thrombotic Thrombocytopenic Purpura (iTTP) is more severe than subsequent relapses; however, existing studies have limitations. We conducted a retrospective observational study to compare analytical and clinical severity of onset and relapse aTTP cases between 2012 and 2023. A total of 370 episodes of aTTP were analyzed, comprising 272 at initial diagnosis and 98 relapses. At onset, analytical parameters indicative of severity (low hemoglobin, low platelet count, and increased LDH) were significantly worse; patients had severe neurological symptoms (p<0.001) and ≥ 3 points in the TMA mortality score (p<0.001). In conclusion, the onset of aTTP is associated with worse analytical parameters and severe neurological involvement.
Literature
1.
go back to reference Domingo-González A, Regalado-Artamendi I, Martín-Rojas RM, Pérez-Rus G, Pérez-Corral A, Díez-Martín JL et al (2021) Application of the French TMA Reference Center Score and the mortality in TTP score in de novo and relapsed episodes of acquired thrombotic thrombocytopenic purpura at a tertiary care facility in Spain. J Clin Apher 36(3):420–428CrossRefPubMed Domingo-González A, Regalado-Artamendi I, Martín-Rojas RM, Pérez-Rus G, Pérez-Corral A, Díez-Martín JL et al (2021) Application of the French TMA Reference Center Score and the mortality in TTP score in de novo and relapsed episodes of acquired thrombotic thrombocytopenic purpura at a tertiary care facility in Spain. J Clin Apher 36(3):420–428CrossRefPubMed
2.
go back to reference Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN (2017) Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv 1(10):590–600CrossRefPubMedPubMedCentral Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN (2017) Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv 1(10):590–600CrossRefPubMedPubMedCentral
3.
go back to reference Lotta LA, Mariani M, Consonni D, Mancini I, Palla R, Maino A et al (2010) Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. Br J Haematol 151(5):488–494CrossRefPubMed Lotta LA, Mariani M, Consonni D, Mancini I, Palla R, Maino A et al (2010) Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. Br J Haematol 151(5):488–494CrossRefPubMed
4.
go back to reference Alvarez-Larrán A, Río-Garma J, Pujol M, Rubia J, Hernández-Jodra M, Borrell M et al (2009) Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: a comparison of presenting clinical characteristics and response to treatment. Ann Hematol 88(10):973–978CrossRefPubMed Alvarez-Larrán A, Río-Garma J, Pujol M, Rubia J, Hernández-Jodra M, Borrell M et al (2009) Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: a comparison of presenting clinical characteristics and response to treatment. Ann Hematol 88(10):973–978CrossRefPubMed
5.
go back to reference Alwan F, Vendramin C, Vanhoorelbeke K, Langley K, McDonald V, Austin S et al (2017) Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood 130(4):466–471CrossRefPubMed Alwan F, Vendramin C, Vanhoorelbeke K, Langley K, McDonald V, Austin S et al (2017) Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood 130(4):466–471CrossRefPubMed
6.
go back to reference Masias C, Wu H, McGookey M, Jay L, Cataland S, Yang S (2018) No major differences in outcomes between the initial and relapse episodes in patients with thrombotic thrombocytopenic purpura: the experience from the Ohio State University Registry. Vol. 93, American Journal of Hematology. Wiley-Liss Inc. p. E73–5 Masias C, Wu H, McGookey M, Jay L, Cataland S, Yang S (2018) No major differences in outcomes between the initial and relapse episodes in patients with thrombotic thrombocytopenic purpura: the experience from the Ohio State University Registry. Vol. 93, American Journal of Hematology. Wiley-Liss Inc. p. E73–5
7.
go back to reference Benhamou Y, Assié C, Boelle PY, Buffet M, Grillberger R, Malot S et al (2012) Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica 97(8):1181–1186CrossRefPubMedPubMedCentral Benhamou Y, Assié C, Boelle PY, Buffet M, Grillberger R, Malot S et al (2012) Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica 97(8):1181–1186CrossRefPubMedPubMedCentral
Metadata
Title
Largest comparison between onset and relapses of acquired thrombotic thrombocytopenic purpura reveals severe neurological involvement and worse analytic parameters at debut
Authors
Blanca Vegas Villalmanzo
Rodrigo Cantera Estefanía
Sara Muñoz Madrid
Mariana Cerrato Salas
Irene Arnaiz Martín
Marta Molina Pérez
Beatriz Sagrista López
Yolanda Ruiz Ramírez
Javier Cucharero Martín
Pablo Estival Monteliú
Paloma Ropero Gradilla
Sara Ferrer Benito
María Paz Martín Hernández
Fernando Ataulfo González Fernández
Miguel Gómez Álvarez
Ana Villegas Martínez
Celina Benavente Cuesta
Jorge Martínez Nieto
Publication date
27-01-2024
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 3/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-024-05634-x

Other articles of this Issue 3/2024

Annals of Hematology 3/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.